CARTRIDGES/YR IN CAPACITY
PRODUCTION CLEAN ROOMS
TOTAL SQUARE FEET
As a fully licensed drug and medical device manufacturer, we have the space, equipment, quality control, and expertise to make technologies and therapies that can change lives for the better.
Our pipeline reflects how we, as well as our partners, are applying MannKind technology to develop and advance new products to not only help people take control of their health, but truly thrive.
MannKind and United Therapeutics entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development of Tyvaso DPI®. As a next-generation formulation of treprostinil, Tyvaso DPI incorporates the dry-powder Technosphere technology and Dreamboat® inhalation device.
MannKind and Cipla Ltd., a global pharmaceutical company, entered into an exclusive supply and distribution agreement for the commercialization of Afrezza® (insulin human) Inhalation Powder in India. Under the terms of the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza® in India as well as all marketing and sales activities. MannKind will manufacture and supply Afrezza to Cipla.
MannKind and BIOMM SA entered into an exclusive supply and distribution agreement for the commercialization of Afrezza® (insulin human) Inhalation Powder in Brazil. MannKind manufactures and supplies Afrezza to Biomm, and Biomm is responsible for promoting and distributing Afrezza within Brazil.
MannKind and Thirona entered into an agreement to evaluate the therapeutic potential of Thirona’s locally acting TGF-β inhibitor, FBM5712, for the treatment of pulmonary fibrosis. MannKind is developing MNKD-501, a dry powder inhaled formulation of FBM5712. If initial studies are promising, MannKind can exercise certain rights to seek a full license to the compound for clinical development and commercialization for the treatment of fibrotic pulmonary diseases.
At our FDA-inspected and approved site, we develop advanced drug delivery systems that use our breakthrough technology.
State-of-the-art development technologies optimize dry powder formulation with inhalation devices early in the development process to ensure successful drug delivery in first-in-human studies.
For chronic therapies
For more acute therapies
The breath-powered inhalers from MannKind are simple, easy to use and discreet. They are disposable, and no cleaning is required. More importantly, they have excellent delivery efficiency.
of therapies and formulations
0.001 mg to 5 mg from a single cartridge
up to 70% of the dry-powder dose deep into the lungs
with small-, medium-, or large-dose cartridges
at a low cost
BluHale helps make our simple inhaler even easier to use. The BluHale connected care ecosystem includes:
For healthcare providers for in-office training on effective inhalation techniques
For consumers has additional sensors to detect device orientation plus dosage strength and timing
The wearable h-Patch drug delivery platform, upon which the V-Go® once-daily wearable insulin delivery device is built, provides a continuous, preset, subcutaneous rate of medication for 1-72 hours via a needle that remains under the skin.
Designed to be patient friendly, the hydraulically engineered device:
Worn like a patch
No complicated technology
No medication by pens or syringes
>1,000 patents in place worldwide
>1,000 utility and >200 design patents
>600 patents provide protection to Afrezza and related technologies.
>150 patents and patent applications*
*INCLUDES WEARABLE H-PATCH DRUG DELIVERY, NEXT GEN DEVICES, METHODS OF USE AND ASSOCIATED TECHNOLOGIES.
The MannKind Fast Feasibility program is designed to rapidly obtain technical feasibility and animal proof of concept by:
Timeline: 1-3 months
Deliverables: Assay, drug loading, particle aerodynamics, drug product stability
Timeline: 1-3 months
Deliverables: PK, bioavailability
Co-author final report
With our innovative Technosphere and h-Patch technologies, our team of dedicated scientists and medical professionals are developing therapeutic products for people with serious medical conditions to help give them control of their health and live life without limits.